CriticalAntiepileptic, hydantoin derivative (sodium channel blocker)×Antianginal – late sodium current inhibitor
Updated · Methodology
Mechanism
The liver breaks down ranolazine mainly through the enzyme CYP3A4 and to a lesser extent through CYP2D6. Ranolazine is also a substrate of the transporter P-glycoprotein (ranolazine label, US Food and Drug Administration, FDA). Phenytoin strongly induces the liver enzymes that metabolise drugs and can lower the levels of drugs cleared by these enzymes (phenytoin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). CYP3A4 inducers are expected to make ranolazine ineffective. Rifampicin 600 mg daily lowers ranolazine levels by about 95%, and the ranolazine documents name phenytoin among these inducers (ranolazine SmPC, European Medicines Agency, EMA, and ranolazine label, FDA). The documents give no figures for phenytoin itself.
Symptoms
Ranolazine is given to adults with stable angina as an add-on when first-line antianginal drugs do not control symptoms or are not tolerated (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). With phenytoin, ranolazine is expected to lose its effect (ranolazine SmPC, EMA), so angina attacks (pressing pain behind the breastbone on exertion) may come back or become more frequent. The fall in ranolazine levels itself causes no symptoms. Stopping phenytoin abruptly can make seizures more frequent and can lead to status epilepticus (phenytoin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination is contraindicated: ranolazine must not be taken with CYP3A inducers, and the US label names phenytoin among them (ranolazine label, US Food and Drug Administration, FDA). The European ranolazine summary of product characteristics (SmPC) says not to use ranolazine in patients taking CYP3A4 inducers, phenytoin among them, and not to start ranolazine during treatment with them (ranolazine SmPC, European Medicines Agency, EMA). Tell the patient that ranolazine must not be taken with phenytoin or other such drugs (ranolazine FDA label). The phenytoin SmPC does not mention ranolazine. According to it, phenytoin strongly induces liver enzymes and can lower the levels of drugs cleared by them (phenytoin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Do not stop phenytoin abruptly: make any dose reduction, withdrawal or switch to another drug gradually (phenytoin SmPC, AEMPS, and phenytoin FDA label). The documents give no interval between stopping phenytoin and starting ranolazine.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- FDA: Dilantin (extended phenytoin sodium capsules) – prescribing information (2023)– FDA label, Viatris Specialty, DailyMed setid 86dd27d1-9cee-48ae-b55d-e2d2f7dbc593, version 3, 08/2023, section 7.2 (Drugs Affected by Phenytoin)
- AEMPS: Ficha técnica: Fenitoína (nº registro 45695), secciones 4.3 y 4.5 (2024)– AEMPS, CIMA, Epanutin 100 mg cápsulas duras, nº registro 45695, revisión 01/2024, secciones 4.3 y 4.5
- EMA: Ficha técnica: Ranolazina, Ranexa (EU/1/08/462), sección 4.4 (2026)– EMA, Ranexa 375 mg comprimidos de liberación prolongada (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08462001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.1, 4.4 y 4.5